BCBoris Calderon

Boris Calderon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Boris Calderon has a total of 185 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials

    by Nasreen Alfaris, Robert F. Kushner, Jianghao Li, Kevin L. Chen, Mia Fenimore, Boris Calderon, Adam Stefanski

    Aims: Tirzepatide is a once‐weekly glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonist (RA) approved for weight management in adults with obesity. Data on older adults remain limited, however. This study aimed to examine tirzepatide's safety and efficacy in adults aged ≥ 65 years with obesity across Phase 3 clinical trials. Materials and Methods: This post hoc analysis evaluated results from the SURMOUNT‐1 through ‐5 (including SURMOUNT‐1 3‐year study), SURMOUNT‐OSA and SUMMIT trials. Efficacy and safety of tirzepatide were compared between participants aged ≥ 65 years and < 65 years. Efficacy outcomes, analysed by study, were assessed at varying points depending on trial design. Safety outcomes in the pooled population were assessed throughout the treatment period. Results: Tirzepatide treatment was associated with clinically meaningful weight reduction and favourable treatment differences in cardiometabolic risk factors and quality‐of‐life measures in adults ≥ 65 years, with broadly comparable results to those observed in adults < 65 years. No clinically meaningful differences in adverse event (AE) rates between tirzepatide and placebo were observed in older adults for gastrointestinal tolerability, falls, fractures, depression outcomes, pancreatitis, and renal, hepatic, gallbladder and biliary‐related AEs. No clinically relevant risks beyond those inherent to older age were detected in adults ≥ 65 versus < 65 years. Conclusions: In this post hoc analysis from Phase 3 clinical trials, efficacy and safety profiles of tirzepatide in adults aged ≥ 65 years with obesity were comparable to those in adults aged < 65 years. This study supports tirzepatide's use in older adults when considering risks and benefits.


  • Open Access

    Correction: Affinity Capture Elution Coupled with Cell-based Cyclic Adenosine Monophosphate Assay as a Platform Method for Detection of Neutralizing Antibodies to Incretin Molecules

    by Nichole A. Reynolds, Yan Q. Chen, Richard E. Higgs, Boris Calderon, Jeff W. Cramer, Nicoletta Bivi, Michael E. Hodsdon, Heather A. Bullock, Travis E. Shockley, Victoria L. Peek, et al.

  • Affinity Capture Elution Coupled with Cell-based Cyclic Adenosine Monophosphate Assay as a Platform Method for Detection of Neutralizing Antibodies to Incretin Molecules

    by Nichole A. Reynolds, Yan Q. Chen, Richard E. Higgs, Boris Calderon, Jeff W. Cramer, Nicoletta Bivi, Michael E. Hodsdon, Heather A. Bullock, Travis E. Shockley, Victoria L. Peek, et al.

    Formation of anti-drug antibodies (ADA) and, in particular, neutralizing antibodies (NAb), is a major risk to the development of biotherapeutics. Cell-based assays, which can reflect the mechanistic interactions among the drug, target, and NAb, are often most suitable for the detection of NAb. We report the development and validation of cell-based platform assays for a class of incretin molecules. An affinity capture elution step was employed to improve drug tolerance of a cell-based cyclic adenosine monophosphate (cAMP) assay. Assay conditions and procedures, including acid elution, cell density, and TAG labeled cAMP (cAMP-TAG) incubation time and concentration, were thoroughly optimized. Delta percent (Δ%) Neutralization was used to reduce assay variability during validation and sample analysis. This platform method has been applied to several incretin molecules and has demonstrated desired sensitivity, drug tolerance, and robustness.

  • Open Access

    Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies

    by Garrett R Mullins, Michael E Hodsdon, Ying Grace Li, Greg Anglin, Shweta Urva, Karen Schneck, Jennifer N Bardos, Ricardo Fonseca Martins, Katelyn Brown, Boris Calderon

    Context: Antidrug antibodies (ADA) can potentially affect drug pharmacokinetics, safety, and efficacy. Objective: This work aimed to evaluate treatment-emergent (TE) ADA in tirzepatide (TZP)-treated participants across 7 phase 3 trials and their potential effect on pharmacokinetics, efficacy, and safety. Methods: ADA were assessed at baseline and throughout the study until end point, defined as week 40 (SURPASS-1, -2, and -5) or week 52 (SURPASS-3, -4, Japan-Mono, and Japan-Combo). Samples for ADA characterization were collected at SURPASS trial sites. Participants included ADA-evaluable TZP-treated patients with type 2 diabetes (N = 5025). Interventions included TZP 5, 10, or 15 mg. ADA were detected and characterized for their ability to cross-react with native glucose-dependent insulinotropic polypeptide (nGIP) and glucagon-like peptide-1 (nGLP-1), neutralize tirzepatide activity on GIP and GLP-1 receptors, and neutralize nGIP and nGLP-1. Results: TE ADA developed in 51.1% of tirzepatide-treated patients. Proportions were similar across dose groups. Maximum ADA titers ranged from 1:20 to 1: 81 920 among TE ADA+ patients. Neutralizing antibodies (NAb) against TZP activity on GIP and GLP-1 receptors were observed in 1.9% and 2.1% of patients, respectively. Less than 1.0% of patients had cross-reactive NAb against nGIP or nGLP-1. TE ADA status, ADA titer, and NAb status had no effect on the pharmacokinetics or efficacy of TZP. More TE ADA+ patients experienced hypersensitivity reactions or injection site reactions than TE ADA– patients. The majority of hypersensitivity and injection site reactions were nonserious and nonsevere, and most events occurred and/or resolved irrespective of TE ADA status or titer. Conclusion: Immunogenicity did not affect TZP pharmacokinetics or efficacy. The majority of hypersensitivity or injection site reactions experienced by TE ADA+ patients were mild to moderate in severity.


  • A Monovalent Fab Affinity-Capture and Elution Bridging Immunoassay Overcomes Rheumatoid Factor Interference while Accurately Detecting Antidrug Antibodies

    by Boris Calderon, Nichole A Reynolds, Craig A Swearingen, Quincy L Carter, Nicoletta Bivi, Jeff W Cramer, Courtney L Alexander, Robert W Siegel, Robert J Konrad

    Background: Rheumatoid factor (RF) consists of autoantibodies that bind the fragment crystallizable (Fc) region of human immunoglobulin G (IgG) and present in sera of rheumatoid arthritis (RA) patients. Immunoassays to detect antidrug antibodies (ADA) in RA patient samples may experience interference due to RF binding and crosslinking Fc regions of the capture and detection antibody reagents. To overcome this interference, a novel Fab affinity-capture and elution (ACE)-bridging immunoassay (Fab ACE-Bridge) was developed with monovalent-recombinant Fab to avoid RF interference. Methods: ACE and ACE-Bridge assays were developed to detect ADA against a therapeutic monoclonal antibody using samples from healthy donors, psoriasis patients, and RA patients. The performance of these assays was compared to a novel Fab ACE-Bridge assay, in which monoclonal antibody was replaced with monovalent Fab. Results: High screening signals in the ACE and ACE-Bridge assays were detected in RA patient samples but not in samples from healthy donors or psoriasis patients. The high screening signals in RA samples did not inhibit to the expected extent in the confirmatory assay, a consistent feature of false-positive screening results. Further investigation revealed RF as the interferent affecting assay performance. Modification of the ACE-Bridge assay by using monovalent Fab eliminated RF interference while allowing for sensitive and drug-tolerant detection of authentic ADA. Conclusions: RF interfered significantly in traditional ACE and ACE-Bridge assays. Implementation of a novel monovalent Fab ACE-Bridge assay overcame RF interference. The use of monovalent Fab is recommended for immunogenicity assays when assessing ADA in RA patient samples.


  • Open Access

    Data from Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

    by Matthew D. Hellmann, Nicoletta Bivi, Boris Calderon, Toshio Shimizu, Brant Delafontaine, Zhuqing Tina Liu, Anna M. Szpurka, Victoria Copeland, F. Stephen Hodi, Sylvie Rottey, et al.

    Purpose:Investigate the safety and efficacy of LY3415244, a TIM-3/PD-L1 bispecific antibody that blocks TIM-3 and PD-L1 in patients with advanced solid tumors.Patients and Methods:A phase I, multicenter, open-label study was conducted in patients with advanced solid tumors. Patients were dosed every 2 weeks intravenously with flat doses of LY3415244 escalating from 3 to 70 mg. The primary endpoints were safety, tolerability, and identification of the recommended phase II dose.Results:Between November 2018 and October 2019, 12 patients were enrolled into four cohorts and received at least one dose of LY3415244. Two patients (16.7%) developed clinically significant anaphylactic infusion-related reactions and all patients developed treatment-emergent antidrug antibodies (TE-ADA). ADA titers were sometimes very high and negatively impacted soluble TIM-3 target engagement in most patients. ADA epitope specificity was against both TIM-3 and PD-L1 arms of the bispecific antibody; most TE-ADAs initially targeted the TIM-3 arm after the first dose. Preexisting ADAs against LY3415244 were also detected in normal (unexposed) human serum samples. One patient with PD-1 refractory non–small cell lung cancer had a near partial response (−29.6%).Conclusions:This TIM-3 and PD-L1 bispecific format was associated with unexpected immunogenicity targeting both arms of the bispecific antibody, resulting in early study termination. Epitope specificity analysis revealed an initial response toward the TIM-3 arm and presence of preexisting ADAs to the bispecific molecule in the general population. This experience emphasizes the importance of thorough analyses for preexisting ADAs as part of immunogenicity risk assessment of novel antibodies.See related commentary by de Spéville and Moreno, p. 2669

  • Open Access

    Supplemental Figure 1 from Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

    by Matthew D. Hellmann, Nicoletta Bivi, Boris Calderon, Toshio Shimizu, Brant Delafontaine, Zhuqing Tina Liu, Anna M. Szpurka, Victoria Copeland, F. Stephen Hodi, Sylvie Rottey, et al.

    The generation of the screening ADA signal and confirmatory inhibition by the affinity-capture elution-bridge assay format.

  • Open Access

    Supplemental Table 1 from Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

    by Matthew D. Hellmann, Nicoletta Bivi, Boris Calderon, Toshio Shimizu, Brant Delafontaine, Zhuqing Tina Liu, Anna M. Szpurka, Victoria Copeland, F. Stephen Hodi, Sylvie Rottey, et al.

    This table contains the baseline patient demographics and disease characteristics.

  • Open Access

    Supplemental Figure 3 from Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

    by Matthew D. Hellmann, Nicoletta Bivi, Boris Calderon, Toshio Shimizu, Brant Delafontaine, Zhuqing Tina Liu, Anna M. Szpurka, Victoria Copeland, F. Stephen Hodi, Sylvie Rottey, et al.

    CD8 positive cells in tumors at baseline and post-treatment

  • Open Access

    Supplemental Table 5 from Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

    by Matthew D. Hellmann, Nicoletta Bivi, Boris Calderon, Toshio Shimizu, Brant Delafontaine, Zhuqing Tina Liu, Anna M. Szpurka, Victoria Copeland, F. Stephen Hodi, Sylvie Rottey, et al.

    A description of the tumor biomarkers.